Company intelligence / Profile preview

Nippon Hypox Laboratories

Ownership: Private
Development stage: Other

Overview

Nippon Hypox Laboratories developed at least two small molecule drug candidates. HX-1171 targeted Nrf2 for neoplasms and atherosclerosis but was discontinued. HX-0836 targeted both 5-lipoxygenase and cyclooxygenase‑2 for hypersensitivity and other indications; its status is listed as "pending," with no evidence of recent clinical progress or approvals. No current clinical results are available, suggesting the company is inactive or has ceased operations[1].

Therapeutic areas: ImmunologyCardiovascularOncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Nippon Hypox Laboratories.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nippon Hypox Laboratories.

Explore the full profile